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Astragalus mongholicus Bunge has long been used to treat cardiovascular disease in Chinese traditional medicine. However, its
mechanisms are not fully understood. In this study, we explored potential mechanisms and protective eﬀects of total ﬂavonoids of
Astragalus (TFA) on cardiovascular disease using in vitro experiments and diet-induced atherosclerotic rabbits. We identiﬁed six
components and their proportion in TFA. The animal experiments showed that TFA signiﬁcantly reduced plasma levels of total
cholesterol and LDL cholesterol (P<0.05 to 0.01), increased HDL cholesterol levels (P<0.01), and reduced the aortic fatty streak
areaby43.6to63.6% (P<0.01).We alsofoundthatTFAscavenged superoxideandhydroxylradicals andthiseﬀectincreasedwith
higher TFA concentration. In in vivo experiments, TFA eﬀectively inhibited the free radical spectrum in the ischemia-reperfusion
module. In conclusion, TFA was the active component of Astragalus mongholicus Bunge, which beneﬁts cardiovascular disease
attributing to the potent antioxidant activity to improve the atherosclerosis proﬁle.
1.Introduction
Traditional Chinese medicine (TCM) has more than ﬁve
thousand years of history. It has made an excellent con-
tribution to human health not only because it is used for
treating many diseases, but also for its beneﬁts in health
maintenance. Astragalus mongholicus Bunge is a qi supple-
ment drug in TCM and has many eﬀects such as lifting the
sunken yang, enhancing the defensive energy and superﬁcial
resistance, promoting pus discharge and tissue regeneration,
and inducing diuresis to cure edema [1]. There have been
many studies with this herb in modern medicine. Results
showed that certain extracts had eﬀects such as improving
immune function and lowering blood pressure [2–5]. A
number of bioactivity studies with speciﬁc components of
this herb, such as saponins and polysaccharides, have also
been published [6, 7]. However, there are few reports on the
bioactivity of the ﬂavonoids of Astragalus.
Flavonoids are found in most parts of the plant and have
been attributed with multiple biological activities such as
anticarcinogenic, anti-inﬂammatory, antibacterial, antiviral
andimmune-stimulatingeﬀects[8–10].Recently,theantiox-
idant activity of ﬂavonoids has given rise to much attention.
Many ﬂavonoids have greater antioxidant activity than the
antioxidant vitamins, vitamin C, vitamin E, and, β-carotene
[11, 12].The aims of this study were to identify whether total
ﬂavonoids of Astragalus (TFA) could inhibit the formation
of atherosclerosis and the potential mechanisms by a series
of experiments.
2. Results
2.1. The Chemical Constituents of TFA
The present study showed that TFA contains six chemical
components including β-sitosterol, formononetin, calycosin,
daucosterol, formononetin-7-O-β-D-glucopyranoside, and
calycosin-7-O-β-D-glucopyranoside. All these components
were consistent with previous reports [13–15]. Their chemi-
cal structures were showed in Figure 1.2 Oxidative Medicine and Cellular Longevity
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Figure 1: The six chemical constituents of TFA.
2.2. Eﬀect of TFA on Atherosclerosis Formation
2.2.1. Body Weight. Body weight is an important parameter
to monitor the general health condition. Our study showed
the average body weight of the rabbits increased 0.52kg in
the normal chow group during the experimental period.
However, the average body weight decreased 0.30kg in the
animals fed high-cholesterol diet. Net body weight in all
treated rabbits was not signiﬁcantly diﬀerent compared with
the high cholesterol-fed alone group (P>0.05).
2.2.2. Plasma Lipid Proﬁle. Table 1 summarized the plasma
lipids proﬁle in the ﬁve groups of animals. Total cholesterol
before exposure to experimental diets in all groups was not
signiﬁcantly diﬀerent. The level of total cholesterol in group
A remained unchanged during the 12-week period, but there
were signiﬁcant increases in all high-cholesterol-fed groups
after4weekscomparedwithgroupA.At4and12weeks,TFA
(and vitamin E plus C) prevented some of the diet-induced
increase in lipid, so their plasma total cholesterol levels in
treated animals were signiﬁcantly lower than those animals
in the high-fat diet without TFA (P<0.05 to P<0.001).
However, the levels of total cholesterol were not signiﬁcantly
diﬀerent in all animals receiving high-cholesterol diet at 8
weeks.
The per diet plasma HDL cholesterol levels in all rabbits
were not diﬀerent. The HDL cholesterol values were also not
signiﬁcantly changed in groups A and B. The values of HDL
cholesterol increased in a time-dependent manner in treated
groups (P < 0.001). In groups C, D, and E, although HDL
cholesterol levels were numerically increased compared with
group B at 12 weeks, the levels were only signiﬁcantly higher
in the group treated with the high dose of TFA (P < 0.01)
(Table 1).
The per diet levels of LDL cholesterol in all experimental
rabbits were not diﬀe r e n t .T h ev a l u e so fL D Lc h o l e s t e r o li n
the normal chow group did not change during the period
of observation, but the levels increased signiﬁcantly and
progressively in all groups receiving high-cholesterol diet
(P<0.001). The data also shows that the levels of LDL
cholesterol were signiﬁcantly reduced by TFA (group E) at 4
and 8 weeks (P<0.001 and P<0.05, resp.) and vitaminOxidative Medicine and Cellular Longevity 3
Table 1: Eﬀect of TFA and combination vitamins on lipid proﬁles in cholesterol-fed rabbits (mmol/L).
Groups Week 0
TC HDL-C LDL-C TG
A0 .83 ±0.34 0.46 ±0.26 0.22 ± 0.15 0.69 ±0.15
B0 .77 ±0.35 0.55 ±0.23 0.30 ± 0.23 0.71 ±0.23
C0 .81 ±0.27 0.53 ±0.27 0.27 ± 0.16 0.53 ±0.12
D0 .88 ±0.35 0.49 ±0.19 0.29 ± 0.23 0.63 ±0.19
E0 .80 ±0.23 0.48 ±0.16 0.22 ± 0.12 0.43 ±0.19
Groups Week 4
TC HDL-C LDL-C TG
A0 .82 ±0.37 0.35 ±0.11 0.18 ± 0.11 0.49 ±0.15
B3 4 .36 ±12.94 0.76 ±0.39 30.91 ±9.53 1.20 ±0.62
C1 5 .06 ±11.50‡ 0.81 ±0.35Δ 14.48 ±10.73Δ‡ 0.79 ±0.35
D2 3 .96 ±9.61 0.67 ±0.19 21.97 ±9.06 0.86 ±0.47
E1 2 .73 ±4.96‡ 0.55 ±0.12 12.85 ±5.15‡ 0.89 ±0.27
Groups Week 8
TC HDL-C LDL-C TG
A0 .76 ±0.34 0.42 ±0.23 0.22 ± 0.11 0.53 ±0.19
B3 6 .55 ±18.86 0.71 ±0.39 43.14 ±17.08 1.52 ±0.97
C2 6 .04 ±17.39 1.34 ±1.20 27.47 ±21.11 1.25 ±0.47
D2 9 .55 ±14.49 0.72 ±0.23 27.18 ±13.87 1.05 ±0.39
E2 2 .16 ±13.52 0.90 ±0.43 21.54 ±9.33∗ 1.36 ±0.78
Groups Week 12
TC HDL-C LDL-C TG
A0 .81 ±0.34 0.40 ±0.11 0.24 ± 0.15 0.52 ±0.34
B5 7 .14 ±14.18 0.86 ±0.31 46.02 ±23.55 2.39 ±2.09Δ
C3 1 .55 ±15.88† 1.77 ±0.62 35.30 ±18.28 1.77 ±0.81∗
D3 7 .57 ±16.96∗ 1.37 ±1.36 35.70 ±17.31 2.21 ±1.12
E3 7 .92 ±19.25∗ 2.35 ±1.36† 37.14 ±18.55 2.08 ±0.97
Group A (n = 14) received normal chow; group B (n = 15) high-cholesterol diet; group C (n = 15) high-cholesterol diet plus vitamin E + C; group D and E
(n = 15 each) high-cholesterol diet plus TFA (60 or 120mg/day, resp.). Data expressed as mean ± SD. ΔP<0.01, P<0.001 compared with group A. ∗P <
0.05, †P<0.05,‡P<0.01 compared with group B.
Ep l u sC( P<0.001) at 4 weeks. However, the levels of
LDL cholesterol were not signiﬁcantly diﬀerent in all treated
groups compared with group B at 12 weeks (Table 1).
Table 1 also showed the levels of plasma triglycerides in
a l lg r o u p sa t0 ,4 ,8 ,a n d1 2w e e k s .T h eg r o u pAh a dn o r m a l
triglyceridelevelsduringtheexperimentperiod.Thelevelsof
triglyceride showed an increasing trend in a time-dependent
manner (P<0.001) in all animals receiving the 1% high-
cholesterol chow. The levels of triglycerides in the animals
treated with vitamin E plus C were signiﬁcantly decreased
compared with group B at 12 weeks (P<0.05). Although
the triglycerides levels in the TFA-treated animals decreased
by 13% bycompared with group B, it was not statistically
signiﬁcant.
2.2.3. Fatty Streaks in the Aorta. The endothelial surface of
the aortic walls was examined for atherosclerotic plaques.
The changes of fatty streak area, the content of total
cholesterolintheaorticarch,andtheratioofintimatomedia
averagethicknessinallthegroupsaresummarisedinTable 2.
The result shows that the high dose of TFA can signiﬁcantly
reduce fatty streak area (P<0.01) and reduce the content
of aortic arch cholesterol (P<0.05), whereas the ratio of
intimatomediaaveragethicknesswasalsomarkedlyreduced
(P<0.001) by both doses of TFA compared with group B.
Treatment with vitamin E plus C also reduced fatty streak
area(P<0.05),reducedthecontentofaorticarchcholesterol
(P<0.05), and reduced the ratio of intima to media average
thickness (P<0.05).
Histological transverse sections of aortas with hema-
toxylin eosin staining were shown in Figure 2. Figures 2(a)
and 2(b) showed that the thickness of internal elastic lamina
is signiﬁcantly increased in cholesterol-fed rabbits compared
tothenormalchowgroup.Whentheaortaweremagniﬁedto
100x or 400x, there were extensive changes with proliferating
smooth muscle cells, numerous foam cells Figures 2(d)
and 2(f), and lipid lakes Figure 2(f) in the fatty plaque in
cholesterol-fed rabbits.
Table 2 also summarised that changes of the cholesterol
content in the aortic arch and the ratio of intima to media4 Oxidative Medicine and Cellular Longevity
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Figure 2: Microscopic sections of aortas with hematoxylin eosin staining. (a), (c), and (e) show the entire aorta, part of aorta with original
magniﬁcation 100x and 400x of normal chow group. (b), (d), and (f) show the aorta changed in the high-cholesterol-fed group with the
entire aorta, part of aorta with original magniﬁcation 100x and 400x, respectively.
Table 2: Eﬀect of TFA and combination vitamins on fatty streak area of the aorta, total cholesterol content in the aortic arch, and ratio of
intima to media average thickness in cholesterol-fed rabbits.
Group Fatty streak area (%) Total cholesterol (mg) Ratio of intima/media thickness
A1 .65 ±1.31 1.12 ±0.30 —
B3 7 .50 ±20.45 25.06 ±20.60 0.66 ±0.31
C2 4 .70 ±6.27∗ 12.04 ±8.83Δ∗ 0.39 ±0.16∗
D2 6 .12 ±12.20 14.27 ±7.75Δ 0.36 ±0.23
‡
E2 2 .92 ±7.51† 11.67 ±6.16Δ∗ 0.32 ±0.12
‡
Data expressed as mean ± SD. ΔP<0.01, P<0.001 compared with group A; ∗P<0.05, †P<0.01, ‡P<0.001 compared with group B.
average thickness in all rabbits. We found that the concentra-
tion of cholesterol in the aortic arch was signiﬁcantly greater
in rabbits which received high-cholesterol food (P<0.001
for all). Compared with group B, the cholesterol content in
theaorticarchwasmarkedlyreducedbythehighdoseofTFA
(P<0.01) and vitamin E plus C (P<0.05).
Furthermore, the changes of the ratio of intima to media
average thickness showed the ratio was signiﬁcantly reduce
by TFA and vitamin E plus C (P<0.001 for both doses TFA,
P<0.05 for vitamins, resp., Table 2).
2.2.4. Blood Glucose. The concentrations of glucose in all
experimental groups were not signiﬁcantly diﬀerent at week
0. They remained unchanged at 4 weeks in all groups and
werenotdiﬀerentfromeachother.TheglucoselevelsshowedOxidative Medicine and Cellular Longevity 5
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Figure 3: Scavenging eﬀect of TFA on superoxide radical; (a)
c o n t r o l ;( b )1 . 2g / LT F A ;( c )0 . 1 2g / LT F A .
h 1 mT
(a)
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(c)
Figure 4: Scavenging eﬀect of TFA on hydroxyl radical; (a) control;
( b )1 . 2g / LT F A ;( c )0 . 1 2g / LT F A .
anincreasingtrendingroupB,butthiswasnotsigniﬁcant.In
the TFA (60mg/day) treated group, despite the glucose levels
increasing about 20–25% at weeks 8 and 12 compared with
group B, this was not signiﬁcant.
2.2.5. Antioxidant Activity. The results for FRAP and α-
tocopherol were summarised in Tables 3 and 4,r e s p e c t i v e l y .
The data showed that vitamin E plus C can signiﬁcantly
increase the levels of FRAP and α-tocopherol after 8 weeks
(P<0.01), whereas there were no signiﬁcant changes of
plasma ascorbate and SOD compared with group B. TFA
did not markedly alter the levels of FRAP, α-tocopherol,
ascorbate, and SOD. Furthermore, no statistical relationship
wasfoundbetweenantioxidantindicesandaorticfattystreak
area (P>0.05).
2.3. In Vitro Scavenging Eﬀect of TFA on Superoxide and
Hydroxyl Radicals. The trapping of the superoxide radicals
by DMPO leads to the formation of the DMPO-OOH
adducts which are measured by ESR. Figure 3(a) shows the
waveform spectrum of the control assay, which corresponds
to the DMPO-OOH adduct, the ﬁrst peak being used in
the analyses. The TFA concentrations of 0.12g/L and 1.2g/L
reduced DMPO-OOH adduct levels by 82.8 ± 1.4% and
94.3 ± 0.8%, respectively, (Figure 3). Figure 4(a) showed the
waveform spectrum of the control assay which corresponds
to the DMPO-OH adduct produced when DMPO traps the
hydroxylradicals,the secondpeak being usedin theanalyses.
TFAat0.12g/Land1.2g/LreducedDMPO-OHadductlevels
by 57.1 ±1.3% and 66.7 ±1.2%, respectively.
2.4. Eﬀect of TFA on Free Radicals In Vivo Following Ischaemic
Reperfusion. At baseline, free radical production was not
identiﬁed in the isolated hearts in the Langendorﬀ system.
However, 1min after recommencement of oxygen perfu-
sion using the Krebs-Hensleit solution following 10min
ischaemia, signiﬁcant free radical production was identiﬁed
(8.9 ± 1.3U / g w t ,Table 5). The introduction of 100mg/L
of TFA signiﬁcantly reduced the levels of free radicals by
46.1, 63.5, and 37.1% after 1,5, and 10min reperfusion,
respectively (P<0.001).
3. Discussion
Astragalus mongholicus Bunge has long been used as a qi
supplement in TCM. Experimental and clinical data shown
that Astragalus has protective eﬀects on cardiomyocyte
damage induced by hypoxia and viral inﬂammation, can
ameliorate atherosclerosis, induced vasodilation and lower
blood pressure [16]. Lu et al. reported that an Astragalus
Angelica mixture could not only reduce the serum levels
of total cholesterol and triglyceride, but also could lower
levels of LDL cholesterol and apolipoprotein B (P<0.05).
Light microscopic and immunohistochemical examination
revealed that the Astragalus Angelica mixture could cause
reduction of glomerular sclerosing index (P<0.01) and
reduced fatty streak area (P<0.01) [17]. Similar results were
also obtained by other experiments in animals [18] and in
clinical studies [19].
In the present study, a major ﬁnding is that TFA, which
is the main active component in Astragalus mongholicus
Bunge,containssixsingleﬂavonechemicalconstituents.TFA
and vitamin E plus C can signiﬁcantly reduce plasma total
cholesterol levels (Table 1), fatty streak area, aortic arch total
cholesterol content, and the ratio of plaque intima/media
thickness (Table 2). The results showed that TFA, at high
dose, can signiﬁcant increase HDL cholesterol and reduce
LDL cholesterol, whereas vitamin E plus C can reduce
triglyceride and LDL cholesterol levels at 4 weeks compared
with high-cholesterol diet alone. Furthermore, our data also
showedthatTFAhasagoodpotentialeﬀectonscavengerfree
radicals in vitro and in vivo.
Hypercholesterolemia is known to be an important
contributing risk factor for atherosclerosis. Our data show
that plasma total cholesterol level in all animals receiving
high-cholesterol diet was signiﬁcantly increased and with a
strong linear relationship with time (P<0.001). In the
early stage of atherosclerosis, TFA and vitamin E plus C
can reduce LDL cholesterol levels. The high dose of TFA
also resulted in increased HDL cholesterol value at the
advanced stage (12 weeks). The combination of vitamin E
plusCcouldsigniﬁcantlylowerplasmalevelsoftriglycerides.
In support of our ﬁndings, a double-masked placebo-
controlled randomized clinical trial has shown that long-
termsupplementationofnondepletedmenwithareasonable6 Oxidative Medicine and Cellular Longevity
Table 3: Eﬀe c to fd i ﬀerent treatments on FRAP activity in cholesterol-fed rabbits (μmoL/L).
Group Week 0 Week 4 Week 8 Week 12
A 297 ±200 332 ±135 229 ±71 264 ±161
B 280 ±108 516 ±364 517 ±198 775 ±430
C 317 ±70 1117 ± 840 1831 ±852‡ 1887 ±813†
D 258 ±101 380 ±151 443 ±132 640 ±403
E 326 ±112 385 ±93 396 ±147 1013 ±856Δ
Data expressed as mean ± SD. P<0.05, ΔP<0.01, P<0.001 compared with group A; †P<0.01, ‡P<0.001 compared with group B.
Table 4: Eﬀect of TFA and vitamins on plasma α-tocopherol levels in cholesterol-fed rabbits (μmol/L).
Group Week 0 Week 4 Week 8 Week 12
A2 .69 ±2.92 2.00 ±2.10 2.05 ±1.83 2.49 ±3.41
B2 .08 ±1.47 24.33 ± 27.96Δ 10.32 ±8.60 19.74 ±20.29
C2 .04 ±1.20 98.00 ±71.57 100.40 ±65.18† 175.00 ±83.39†
D2 .67 ±3.21 22.05 ± 13.40Δ 18.88 ±20.06Δ 32.59 ±31.52Δ
E2 .00 ±3.87 15.93 ±12.28 16.62 ±16.96Δ 18.11 ±17.16Δ
Data expressed as mean ± SD.P<0.05,ΔP<0.01, P<0.001 compared with group A; †P<0.01 compared with group B.
dose of vitamin E alone or in combination with slow release
vitamin C reduces lipid peroxidation [20]. However, in
previous reports by Kinlay et al. [21] and by Sun et al. [22],
they did not demonstrate a signiﬁcant protective eﬀect on
lipids in human and animal. Thus, it is plausible that the
eﬀects of TFA and the combination of vitamin E plus C on
lipid metabolism might be involved in other mechanisms in
addition to the antioxidant.
The role of modiﬁcation LDL in atherosclerosis has been
a topic of considerable interest and attention. Antioxidants
in plasma may have beneﬁts by inhibition of the formation
of atherosclerosis. Some large epidemiological studies have
revealed that vitamin E levels in plasma are inversely
correlatedtotheincidenceofcoronaryheartdisease[23,24].
Considerable amounts of data for the role of vitamin E in
prevention of atherosclerosis have been published [22, 25,
26]. The main potential mechanisms of vitamin E to protect
against atherosclerosis include inhibition of LDL oxidation
[27], inhibition of leukocyte adhesion to the endothelium,
and improvement of vascular endothelial dysfunction [28].
Nagyov` a et al. reported that plasma total antioxidant status
aﬀected the TBASR levels of LDL [29]. Our data show that
the levels of FRAP and α-tocopherol signiﬁcantly increased
with vitamin E plus C in a time-dependent manner (P<
0.001,P<0.001,resp.).ThelevelsofFRAPandα-tocopherol
also showed a good correlation relationship (P<0.001).
Therefore, FRAP activity is likely to reﬂect vitamin E intake.
According to the oxidative modiﬁcation hypothesis, the
protective eﬀect of vitamin E plus C against atherosclerosis
development should be better than TFA because the FRAP
levels were signiﬁcantly higher. However, the results showed
thattheeﬀectofvitaminEplusCandTFAonatherosclerosis
indices (the fatty streak area, total cholesterol content in the
arch of the aorta, and the ratio of aortic intima to media
average thickness) was not signiﬁcantly diﬀerent. Similar
results have been reported by Sun et al., that the values of α-
tocopherolweresigniﬁcantlyhigherin serumandtissueafter
taking vitamin E and C in cholesterol-fed rabbits, but there
was no signiﬁcant reduction in aortic fatty streak area [22].
One study reported that 2% garlic extract could signiﬁcantly
reduce the atheromatous plaques but the antioxidant marker
SOD did not change [30]. Another study showed that the
antioxidants such as vitamin E and probucol have diﬀerent
eﬀects on atherosclerosis formation and suggested that this
may be due to the diﬀerent antioxidant properties [31].
Furthermore, we found no relationship between fatty streak
area and plasma levels of antioxidant indices, despite some
of them being signiﬁcantly increased in treated animals.
Therefore, the mechanism by which antioxidants inhibit
atherosclerosis formation may be related to other pathways
in addition to increasing the resistance of LDL to oxidation.
However, the role of these indices of antioxidant activity
such as FRAP, ascorbate, bilirubin, SOD, and α-tocopherol
as markers of antioxidant inhibition in atherosclerosis still
requires further evidence.
Increasing numbers of studies have on ﬂavonoids. Some
of the studies demonstrated that ﬂavonoids appear to be
associated with reduction of the risk of cardiovascular
diseases [32, 33] and retarding atherosclerosis [34]. Several
studies have shown that the main mechanism by which
ﬂavonoids inhibit the development of fatty streak lesions
in atherosclerosis was reduction in LDL oxidation [35, 36].
Furthermore,Fuhrman et al. reported that macrophage
enrichment with polyphenolic ﬂavonoids in vitro or in vivo
reduced the macrophage oxidative state and subsequently
cell-mediated oxidation of LDL [36]. An in vitro study
of the eﬀect of tea ﬂavonoids on the susceptibility of
LDL to oxidative modiﬁcation showed that tea ﬂavonoids
signiﬁcantly and dose-dependently prolonged the lag time
of LDL oxidation (P<0.01). Macrophage-mediated LDL
oxidation was also inhibited by adding these tea ﬂavonoids
[37]. Yokozawa et al. demonstrated that black tea extract
inhibited the proliferation of smooth muscle cells involved
in the development and progression of atherosclerosis andOxidative Medicine and Cellular Longevity 7
Table 5: Free radical-PBN adduct (U/gwt).
Group Baseline Reperfusion for 1  Reperfusion for 5  Reperfusion for 10 
Control 0 8.92 ± 1.32 12.62 ± 2.28 8.42 ± 0.99
TFA 0 4.83 ± 0.67∗ 3.56 ± 0.74∗ 5.25 ± 0.51∗
n = 8, ∗P<0.05, compared with control.
suppressed the production of oxidised LDL [38]. Ismail et al.
suggested that the eﬀect of fresh garlic to lower cholesterol
could be mainly attributed to its ﬂavonoid constituents
[30].
Flavonoids are naturally occurring plant-based free rad-
ical scavengers, and many ﬂavonoids have been reported
to possess better antioxidant properties than α-tocopherol
when assessed by the in vitro oxygen radical absorbency
capacity method [39]. The ﬂavonoids scavenge free radicals
by acting as a hydrogen atom donor to the free radical
during the oxidation-reduction reaction [40]. TFA, which
contains several types of ﬂavonoids, has the main active
components of Astragalus mongholicus Bunge. The ﬂavonoid
extracts of Astragalus mongholicus B u n g eh a v eb e e nr e p o r t e d
to contain diﬀerent quantities of phenolic hydroxyl [41].
Our data showed that TFA eﬀectively reduced the levels
of superoxide and hydroxyl radicals in a dose-dependent
manner and also signiﬁcantly reduced free radical levels
following ischaemia/reperfusion in the isolated rat hearts.
In conclusion, the beneﬁts of Astragalus mongholicus
Bunge in cardiovascular diseases such as atherosclerosis
may be due to TFA. The potential mechanism of the TFA
antioxidant eﬀect may contribute to inhibit atherosclerosis.
4.MaterialsandMethods
4.1. Extraction and Puriﬁcation of TFA. The roots of Astra-
galus mongholicus Bunge, sourced from Inner Mongolia,
China, were sliced and macerated in 95% ethanol and then
extracted. The ethanol extraction of the solid material was
repeatedfourtimesandthepooledextractthenconcentrated
to a speciﬁc gravity of 1.35 by evaporation. The concentrated
solution was extracted with ethyl acetate. The concentrated
ethyl acetate extract was further separated by diﬀerent types
of silica gel columns. TFA contains six main chemical com-
ponents identiﬁed by ultraviolet spectrum, nuclear magnetic
resonance, and mass spectra.
4.2. Drugs and Reagents. Vitamin E (Banner Gelatin Prod-
ucts Corp., CA, USA) was obtained from Well Favoured Ltd
of Hong Kong. Vitamin C (Roche Company) was purchased
at Watson’s supermarket. 5,5-Dimethyl-1-pyrroline-1-oxide
(DMPO), α-phenyl-N-tert-butylnitrone (PBN), diethyltri-
amine pentaacetic acid (DETAPAC), hypoxanthine (HX),
xanthine oxidase (XO), ferrous sulfate, and hydrogen per-
oxide were purchased from Sigma Chemicals (Sigma Chem-
icals, St. Louis, MO, USA) and were of the highest grade
available. DMPO was puriﬁed with activated charcoal before
use. TFA was prepared in our laboratory.
4.3. Animals Treatment in Atherosclerosis Formation Model.
A total of seventy-four male New Zealand white rabbits
weighing2.7–3.5kgwereprovidedbytheLaboratoryAnimal
Services Centre of the Chinese University of Hong Kong. The
animals were housed individually with a 12-hour light cycle,
55 ± 5% of relative air humidity, and room temperature of
20±2◦C,fedstandardcommercialchow(GlenForrestStock-
feeds,WesternAustralia,Australia)andwateradlibitum.The
rabbits were randomly assigned to 5 groups. Group A (n =
14) received normal chow. Group B (n = 15) received high-
cholesterol diet (1% cholesterol diet, Glen Forrest Stockfeeds
Company, Australia) alone. Group C (n = 15) was given
high cholesterol diet plus vitamin E + C (400IU/day and
500mg/day, resp.). Group D and E (15 rabbits each) were
given high-cholesterol diet plus TFA (60 or 120mg/day,
resp.). All the drugs were given by gavage. Fasting blood
was drawn from all the animals at weeks 0, 4, 8, and 12
for plasma lipid concentrations and antioxidant capacity
analysis. After 12 weeks, the rabbits were sacriﬁced by CO2.
The aorta was separated from the heart at the aortic valve.
The ﬁrst 5mm from the heart was ﬁxed in 10% formalin
buﬀer solution for subsequent histopathological analysis.
Another part of the aorta was used for aortic fatty streak area
analyses and total cholesterol content determination. This
experimental protocol was approved by the Animal Research
Ethics Committee of the Chinese University of Hong Kong.
4.4. Plasma Lipid Assays and Aortic Arch Cholesterol Measure-
ments. Total cholesterol, HDL cholesterol, LDL cholesterol,
and triglyceride were measured using enzymatic methods
(Roche Diagnostic Systems, Basel, Switzerland) on a Cobas
Fara centrifugal analyser (Roche, Basel, Switzerland).
Aortic arch cholesterol content was measured by the
method described by Carr et al. with some modiﬁcation
[42]. The aortic arch was homogenised with 50mg of
sodium sulphate and 8mL of extraction solution containing
chloroform/methanol (2:1), transferredto another tube and
thetissuehomogenisedasecondtimefollowedbyadditionof
3mL of extraction solution. After mixing, 3mL of a solution
containing 1.25% KCL and 0.05% H2SO4 was added and
centrifuged at 400g at room temperature for 10min. The
bottomlayerwastransferredandthesupernatantreextracted
with 3mL of extraction solution and centrifuged at 400g
at room temperature for 10min. The bottom layer was
transferred and pooled with the previous step. The solution
was concentrated in a 40◦C warming bath and placed
under N2 gas. When approximately half of the solution
was evaporated, 1mL of chloroform with 1% Triton-100
was added, mixed, and evaporated to dryness. Then, 500μL8 Oxidative Medicine and Cellular Longevity
distilled water was added to the samples, which were shaken
at 37◦C for 30min to dissolve the lipid. Hepatic tissue
total cholesterol concentration was determined using an
enzymatic method on a model KC4 microplate reader (Bio-
Tek Instruments, Inc., USA) at 490nm wave length.
4.5. Gross and Histologic Appearance of Aortic Wall. Aortas
were stained by immersion for 2 hours in Sudan III. Luminal
surfaces were digitally imaged by scanning (Scan Jet 5100C,
Hewlett Packard), and the percentage of fatty-streak surface
area was determined by digitising the colour images using
the MetaMorph Imaging System (Universal Imaging Corp.,
USA). After the ﬁrst portion of the aorta was ﬁxed in
10% formalin buﬀer solution for 48h, it was embedded in
paraﬃn. Paraﬃns e c t i o n so f4μm thickness of aortas were
cut and stained with standard hematoxylin-eosin stain. Four
sections were cut from each block.
4.6. Parameters of Antioxidant Capacity. Total antioxidant
power of the plasma was measured using the ferric reducing
ability of plasma (FRAP) assay [43]. α-Tocopherol was
measured by a ﬂuorimetric micromethod [44], using pure
(>98%) DL-α-tocopherol (Merck, Darmstadt, Germany) as
calibrator. Ascorbate was measured by the Cobas Fara cen-
trifugal analyzer (Roche Diagnostics Ltd, Basel Switzerland)
[45]. The plasma level of superoxide dismutase (SOD) was
measured using luminolchemiluminescence [46].
4.7. Free Radical Scavenging Eﬀect of TFA In Vitro. Superox-
ide radicals were generated from a hypoxanthine-xanthine
oxidase reaction system, trapped by DMPO, and the spin
adduct (DMPO-OOH) analysed using an ESR spectrom-
eter (Bruker ESP-300 spectrometer, Ettlingen, Germany)
[47]. The procedure was as follows: the reaction solution
25μL which contains 0.43mmol/L HX, 160mmol/L DMPO,
1mmol/L DETPAC, 70U/L XO, and 25μLo f0 . 0 5m o l / Lp H
7.4 PBS or TFA (ﬁnal concentration 0.12 or 1.2g/L) was
mixed. 50μL were then transferred into an ESR quartz cell
immediately for assaying the spin adduct of DMPO-OOH.
Each sample was repeated 4 times.
Hydroxyl radicals were generated from the Fenton
methodology in tubes containing 0.6mmol/L H2O2,
5mmol/L EDTA, 80mmol/L DMPO, and 0.2mmol/L
ferrous sulphate. 25μL of this solution and 25μLo f
0.05mol/L pH 7.4 PBS or TFA (ﬁnal concentration 0.12 or
1.2g/L) were mixed and transferred to an ESR quartz cell
immediately [47]. Analysis of the spin adduct (DMPO-OH)
was performed with an ESR spectrometer. Each sample was
repeated 4 times.
The spectrometer settings were as follows: X band
modulation frequency 25kHz; modulation amplitude 1G;
scan width 100G; microwave power 10mW; time constant
20ms; centre magnetic ﬁeld 3470G; magnetic frequency
9.7GHz. The scavenging rate was calculated based on the
peak-trough height (h, Figures 1 and 2). The 1st and
2nd spectrum peaks were used for the superoxide and
hydroxylradicals,respectively,andcomparedtothoseforthe
controlgroup.Scavengingrate(%)=[(averagecontrolgroup
peak-trough height−test group peak-trough height)/average
control group peak-trough height] × 100.
4.8. Free Radical Scavenging Eﬀect of TFA in Isolated Perfused
Hearts. A total of 20 Wister rats, 220–250g, 50% male,
were provided by the Laboratory Animal Services Centre
of the Chinese PLA General Hospital, Beijing, China. The
rats were randomly divided into the control and TFA
(100mg/L) treated groups. The rats were anaesthetised with
1% pentobarbital (i.p., 40mg/kg) and then given 200IU
heparin. The chests of the unconscious rats were opened
and the hearts isolated and introduced to the Langendorﬀ
system. The 37◦C, pH 7.2–7.4 perfusion solution consisted
of Krebs-Henseleit solution, containing 3mmol PBN [48]
and was saturated with 95% oxygen and 5% carbon dioxide
prior to use. The gas was applied to the perfusion solution
at 1.5 L/min at a pressure of 7.09kPa. The conditions were
the same for both groups except that the perfusion ﬂuid for
theTFA-treatedgroupcontained100mg/LTFA.Theisolated
hearts were perfused for 15min, and then the system was
closed for 10min leading to ischaemia in the hearts. The
system was then reperfused for 10min. The perfusate was
collected at baseline and 1, 5, and 10min after reperfusion
for measurement of free radicals. This experimental protocol
was approved by the Medical Ethics Committee on Research
Practice at the Chinese PLA General Hospital.
To the perfusion solution (3mL/sample), 0.5mL methyl-
benzene was added. The supernatant, following centrifuga-
tion at 800rpm for 5min, was removed for determination
of the free radical concentration using the ESR spectrometer
[49]. The free radical signal was proportional to the concen-
tration of the PBN adducts. The peak-trough height of the
center peak was measured (mm) and the concentration of
the free radical-PBN adduct expressed as the released units
per min per g of wet heart muscle tissue (U/min.g).
4.9. Statistical Analysis. The values are presented as mean ±
SD. The Bonferroni test was used to ﬁnd the statistical
signiﬁcance between groups and drugs. A probability value
of less than 0.05 was considered signiﬁcant. All the analyses
were conducted using SPSS software (Version 10.0, 1999).
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